The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Target Recruit Count
- 16
- Registration Number
- NCT03180333
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: PNA 40mgDrug: PNA 240mgDrug: PNA 160mgDrug: PNA 80mgDrug: PNA PlaceboDrug: PNA 480mgDrug: PNA 360mg
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Target Recruit Count
- 48
- Registration Number
- NCT03173599
- Locations
- 🇨🇳
Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China
The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis
Phase 4
- Conditions
- Bacterial Vaginosis
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Target Recruit Count
- 300
- Registration Number
- NCT03080740
- Locations
- 🇨🇳
Peking University first hospital, Beijing, China
The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B
Phase 2
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Metacavir Enteric-coated Capsules 80mgDrug: Metacavir Enteric-coated Capsules 320mgDrug: Metacavir Enteric-coated Capsules Placebo 320mgDrug: Metacavir Enteric-coated Capsules 160mgDrug: Metacavir Enteric-coated Capsules Placebo 160mgDrug: Metacavir Enteric-coated Capsules Placebo 240mg
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Target Recruit Count
- 180
- Registration Number
- NCT02965859
- Locations
- 🇨🇳
81 Military Hospital of China, Nanjing, Jiangsu, China
The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Target Recruit Count
- 44
- Registration Number
- NCT02889822
- Locations
- 🇨🇳
The Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China
A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
Phase 2
- Conditions
- Arteriosclerosis Obliterans
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Target Recruit Count
- 160
- Registration Number
- NCT02877173
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection
Completed
- Conditions
- Acute Upper Respiratory Infection
- Interventions
- Drug: Low-dose of Fuganlin Oral LiquidDrug: High-dose of Fuganlin Oral Liquid
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Target Recruit Count
- 2400
- Registration Number
- NCT02654158
- Locations
- 🇨🇳
Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)
Phase 4
Completed
- Conditions
- Acute Upper Respiratory Infection
- Interventions
- Drug: Fuganlin Oral LiquidDrug: Xiaoer Jiebiao Oral Liquid
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Target Recruit Count
- 468
- Registration Number
- NCT02622659
- Locations
- 🇨🇳
Luohe traditional Chinese medicine hospital, Luohe, Henan, China
© Copyright 2025. All Rights Reserved by MedPath